In one paragraphReview in American journal of physiology. Lung cellular and molecular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Mrinmay ChakrabartiCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-2681-6134 Mollie PhillipsCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
Rana DharCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
Ansley HerronDepartment of Chemical Engineering, College of Engineering and Computing, University of South Carolina, Columbia, South Carolina, United States.
Jason L KubinakDepartment of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.
Kiesha WilsonDepartment of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0001-8550-3739 E Angela MurphyDepartment of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-4803-5822 Mohamad AzharDepartment of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0001-9228-8096 Colin E EvansCardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia, South Carolina, United States.ORCID 0000-0002-9251-357X Funding
South Carolina IDeA Networks of Biomedical Research (SC INBRE V)P20GM103499 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI EDIE C GOLDSMITH · 2012 to 2026
$61.0MTargeting NMDA Receptors and Brain Estradiol to Rescue Memory in Aging FemalesP20GM109091 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI RONINSON, IGOR B · 2014 to 2024
$25.2MThe Center for Clinical and Translational Research at the University of South Carolina (CLINTRUSC)P20GM155896 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JAMES R HEBERT, FRANCIS G SPINALE · 2024 to 2026
$9.5MTransnational Research Imaging Core (TRI)P30GM131959 · NIGMS · CLEMSON UNIVERSITY · PI VYAVAHARE, NAREN R · 2019 to 2023
$5.9MA Transdisciplinary Approach to Investigating Metabolic Dysregulation in Obese Parent and Child Dyads and Risk of Colorectal Cancer - admin supplementU01CA272977 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JAMES R HEBERT, Lorne J Hofseth · 2022 to 2026
$4.7MB-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut MicrobiotaR01AI155887 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L · 2021 to 2025
$2.1MAnalysis of TGFbeta ligands function in heart development and diseaseR01HL126705 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI AZHAR, MOHAMAD · 2015 to 2018
$1.4MTransformation of metal oxide nanomaterials in wildland-urban interface fires causes congenital heart diseaseR21ES037105 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI AZHAR, MOHAMAD · 2025 to 2025
$410kDevelop natural compound emodin as a novel therapy for calcific aortic valve diseaseR41HL172481 · NHLBI · ACEPRE, LLC · PI AZHAR, MOHAMAD · 2024 to 2024
$300kAmerican Heart Association (AHA) 23SCEFIA1155876American Heart Association (AHA) 24TPA1285575HHS | NIH | National Institute of General Medical Sciences (NIGMS) P20GM103499NCI NIH HHS U01 CA272977NHLBI NIH HHS R01 HL126705NHLBI NIH HHS R41 HL172481NIAID NIH HHS R01 AI155887NIEHS NIH HHS R21 ES037105NIGMS NIH HHS P20 GM103499NIGMS NIH HHS P20 GM109091NIGMS NIH HHS P20 GM155896NIGMS NIH HHS P30 GM131959
6 · The paper itselfAbstract
Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) are inflammatory conditions with substantial rates of morbidity and mortality, but no effective treatments. The lack of effective treatments and unacceptably high mortality rates for ARDS are partly due to an incomplete understanding of the mechanisms that control ALI/ARDS and subsequent vascular repair. Transforming growth factors (TGFs) are a class of growth factors that regulate the vascular response to inflammation, including migration, proliferation, and differentiation of cells comprising the lung vasculature. Here we review studies that describe the impact of the TGF family on inflammatory lung injury and subsequent vascular repair and fibrosis. We highlight gaps in understanding TGF isoform-specific roles in ALI/ARDS and outline directions for future research in the field of TGF-dependent regulation of inflammatory lung injury and vascular repair. Functional roles of the TGFs have been investigated in ALI/ARDS pathogenesis and pulmonary fibrosis, with a predominance for studies showing a proinjurious and profibrotic impact of TGF-β1. Studies have also shown that TGF-α is positively associated with inflammatory lung injury and fibrosis. However, the contributions of TGF-β2 and TGF-β3 to ALI/ARDS are unclear, and the contributions of all the TGF isoforms to vascular repair after ALI/ARDS are not well characterized. Improved understanding of the regulation of inflammatory lung injury and repair by the TGFs could lead to the development of a safe and effective treatment strategy for patients with ALI/ARDS.
Indexed as
Acute Lung InjuryRespiratory Distress SyndromeTransforming Growth FactorsAnimalsHumansInflammationLungPulmonary FibrosisTransforming Growth Factorsinflammationinjurylungrepairtransforming growth factor
Identifiers
PMID40920668
PMCPMC12539375
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390